Siblings 圖書 [1/1] 期刊論文 [327/330] Collection Statistics 近3年內發表的文件:16(8.94%) 含全文筆數:115(64.25%) 文件下載次數統計 下載大於0次:115(100.00%) 下載大於100次:112(97.39%) 檔案下載總次數:39303(22.07%) 最後更新時間: 2024-12-01 07:53 Top Upload Loading... Top Download Loading... Recent Submissions Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Risk of type 2 diabetes mellitus an... Phase 1 studies of D07001-F4 and D0... Updated overall survival (OS) from ... Outcomes of post-immunotherapy dura... Updated overall survival (OS) from ... Updated results of the FOENIX-CCA2 ... Comparative genomic analysis and it... A phase II trial of nivolumab, gemc...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 51-60 of 179. (18 Page(s) Totally) << < 1 2 3 4 5 6 7 8 9 10 > >> View [10|25|50] records per page

Date	Title	Relation
2018-06	The effect of best response to prior anticancer therapy on efficacy outcomes in the napoli-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-152.
2018-06	Decreased appetite (DA) at baseline impacts prognosis in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-153.
2018-06	Prognostic effect of primary tumor location in the NAPOLI-1 phase 3 study in metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-150.
2018-06	Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract O-004.
2018-06	Prognostic value of baseline biliary stents on outcomes in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the NAPOLI-1 trial	Annals of Oncology. 2018 Jun;29(Suppl. 5):Meeting Abstract P-151.
2018-05	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Abstract number e15127.
2018-05	A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers	Journal of Clinical Oncology. 2018 May;36(15, Suppl. S):Meeting Abstract 2556.
2018-05	A survival prediction nomogram for liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy	Journal of Clinical Oncology. 2018 May;36(15, Suppl.):Meeting Abstract e16204.
2018-02	Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)+/- 5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pan	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 460.
2018-02	Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) +/- 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1.	Journal of Clinical Oncology. 2018 Feb;36(4, Suppl.):Abstract number 459.

Showing items 51-60 of 179. (18 Page(s) Totally) << < 1 2 3 4 5 6 7 8 9 10 > >> View [10|25|50] records per page